AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 191 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 3.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $339 | -52.8% | 14,755 | -42.3% | 0.01% | -64.3% |
| Q4 2022 | $718 | -99.9% | 25,565 | +14.4% | 0.01% | 0.0% |
| Q3 2022 | $632,000 | +25.4% | 22,344 | -1.7% | 0.01% | +7.7% |
| Q2 2022 | $504,000 | -78.2% | 22,728 | -71.4% | 0.01% | -75.9% |
| Q1 2022 | $2,309,000 | -16.2% | 79,335 | -5.3% | 0.05% | +17.4% |
| Q4 2021 | $2,755,000 | +594.0% | 83,815 | +989.9% | 0.05% | +475.0% |
| Q1 2021 | $397,000 | -63.3% | 7,690 | -69.2% | 0.01% | -74.2% |
| Q4 2020 | $1,082,000 | -45.1% | 24,967 | -55.7% | 0.03% | -64.0% |
| Q3 2020 | $1,972,000 | +118.9% | 56,338 | +234.4% | 0.09% | +91.1% |
| Q2 2020 | $901,000 | +101.1% | 16,845 | +21.9% | 0.04% | +200.0% |
| Q3 2019 | $448,000 | -2.0% | 13,815 | +50.8% | 0.02% | +15.4% |
| Q2 2019 | $457,000 | +116.6% | 9,161 | +382.2% | 0.01% | +116.7% |
| Q2 2015 | $211,000 | -8.7% | 1,900 | -7.8% | 0.01% | -25.0% |
| Q4 2014 | $231,000 | – | 2,061 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |